7.79
7.79 (0%)
As of Feb 14, 2025
Aurinia Pharmaceuticals Inc. [AUPH]
Source:
Company Overview
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs.
| Country | United States |
| Headquarters | edmonton |
| Phone Number | 250-744-2487 |
| Industry | manufacturing |
| CEO | Peter Greenleaf |
| Website | www.auriniapharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $235.1 |
| Operating Profit | $-4.7 |
| Net Income | $5.8 |
| Net Cash | $34.6 |
Profit Ratios
| Gross Margin | $206.9 |
| Operating Margin | -2 |
| Profit as % of Revenues | 3,596.8% |
| Profit as % of Assets | 1.1% |
| Profit as % of Stockholder Equity | 1.5% |
Management Effectiveness
| Return on Equity | 1.5% |
| Return on Assets | 1% |
| Turnover Ratio | 42.8% |
| EBITA | $-4.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $550.6 |
| Total Liabilities | $173.2 |
| Operating Cash Flow | $44.4 |
| Investing Cash Flow | $39.3 |
| Financing Cash Flow | $-49.1 |
